Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of ADASUVE in Children and Adolescents
NCT02184767Phase 1Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jul 2014
- Primary completion
- Mar 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of loxapine in schizophrenia, bipolar disorder (BD) and Autism Spectrum Disorder (ASD), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Area Under the Plasma Concentration-Time Curve from Time 0 to Last Measurable Concentration at 48 hours. Started Jul 2014; status: completed.
02
Drugs
loxapine
03
Conditions
schizophreniabipolar disorder (BD)Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT02184767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02184767.